BRIEF — Amneal to launch second generic competitor to Lundbeck's Sabril

Amneal is the second firm to launch a line of generic vigabatrin in the US market, after Par Pharmaceuticals receieved FDA approval and launched in 2017. There are fears that this launch could bring about further decline in Lundbeck's share of the vigabatrin market, which was worth $318 million last year.

Andy Boyer, executive vice president for commercial operations at Amneal, said: “We are pleased to add this critical, specialty product to our catalog. Bringing a second generic option to this small patient population exemplifies our commitment to delivering products with value to patients and the healthcare system.”